BRPI0409879A - composições e métodos para imunoterapia especìfica wt1 - Google Patents

composições e métodos para imunoterapia especìfica wt1

Info

Publication number
BRPI0409879A
BRPI0409879A BRPI0409879-0A BRPI0409879A BRPI0409879A BR PI0409879 A BRPI0409879 A BR PI0409879A BR PI0409879 A BRPI0409879 A BR PI0409879A BR PI0409879 A BRPI0409879 A BR PI0409879A
Authority
BR
Brazil
Prior art keywords
compositions
methods
polypeptide
specific immunotherapy
specific
Prior art date
Application number
BRPI0409879-0A
Other languages
English (en)
Inventor
Alexander Gaiger
Patricia D Mcneill
Nomalie Jaya
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of BRPI0409879A publication Critical patent/BRPI0409879A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSIçõES E MéTODOS PARA IMUNOTERAPIA ESPECìFICA WT1". Composições e métodos para terapia de doenças malignas, como leucemia e câncer, são divulgados. As composições compreendem um ou mais de um polinucleotídeo WT1, um polipeptídeo WT1, uma célula apresentadora de antígeno apresentando um polipeptídeo WT1, um anticorpo que se liga especificamente a um polipeptídeo WT1; ou uma célula T que reage especificamente com um polipeptídeo WT1. Tais composições podem ser usadas, por exemplo, para a prevenção e tratamento de doenças metastáticas.
BRPI0409879-0A 2003-04-30 2004-04-29 composições e métodos para imunoterapia especìfica wt1 BRPI0409879A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/427,717 US7553494B2 (en) 2001-08-24 2003-04-30 WT1 fusion proteins
PCT/US2004/013240 WO2004100870A2 (en) 2003-04-30 2004-04-29 Compositions and methods for wt1 specific immunotherapy

Publications (1)

Publication Number Publication Date
BRPI0409879A true BRPI0409879A (pt) 2006-05-16

Family

ID=33449619

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409879-0A BRPI0409879A (pt) 2003-04-30 2004-04-29 composições e métodos para imunoterapia especìfica wt1

Country Status (16)

Country Link
US (2) US7553494B2 (pt)
EP (1) EP1617863A4 (pt)
JP (1) JP2007515393A (pt)
KR (1) KR20060054176A (pt)
CN (1) CN1816349A (pt)
AU (1) AU2004238226A1 (pt)
BR (1) BRPI0409879A (pt)
CA (1) CA2523943A1 (pt)
CO (1) CO5700788A2 (pt)
MA (1) MA27873A1 (pt)
MX (1) MXPA05011755A (pt)
NO (1) NO20055347L (pt)
RU (1) RU2005137167A (pt)
TW (1) TW200509967A (pt)
WO (1) WO2004100870A2 (pt)
ZA (1) ZA200509609B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102198266A (zh) * 1998-07-31 2011-09-28 株式会社国际癌症免疫研究所 基于癌抑制基因wt1的产物的癌抗原
US7329410B1 (en) * 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7901693B2 (en) * 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
ATE383375T1 (de) * 2001-03-22 2008-01-15 Int Inst Cancer Immunology Inc Wti-modifiziertes peptid
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US20050260217A1 (en) * 2004-03-04 2005-11-24 Corixa Corporation Co-encapsulated WT1 polypeptide and immunostimulant microsphere formulations and methods thereof
ES2531142T3 (es) 2005-10-17 2015-03-11 Sloan Kettering Inst Cancer Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
WO2007120673A2 (en) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
TWI480552B (zh) * 2006-08-14 2015-04-11 Academia Sinica 胃液蛋白分析於胃癌鑑定之方法
AU2012227350C1 (en) * 2006-12-28 2015-11-12 International Institute Of Cancer Immunology, Inc. HLA-A*1101-Restricted WT1 peptide and pharmaceutical composition comprising the same
WO2008081701A1 (ja) * 2006-12-28 2008-07-10 International Institute Of Cancer Immunology, Inc. Ｈｌａ－ａ＊１１０１拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物
WO2008105462A1 (ja) * 2007-02-27 2008-09-04 International Institute Of Cancer Immunology, Inc. ヘルパーｔ細胞の活性化方法およびそのための組成物
EA018201B1 (ru) * 2007-05-24 2013-06-28 Глаксосмитклайн Байолоджикалс С.А. Лиофилизированная антигенная композиция
EP3539567A1 (en) 2007-07-02 2019-09-18 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
WO2012129514A1 (en) * 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
WO2012135854A2 (en) * 2011-04-01 2012-10-04 Memorial Sloan-Kettering Cancer Center Antibodies to cytosolic peptides
CN104684577B (zh) 2012-01-13 2018-05-08 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
WO2014031178A1 (en) * 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
CN104812401B (zh) 2012-12-13 2017-10-13 宾夕法尼亚大学理事会 Wt1疫苗
PT2945647T (pt) 2013-01-15 2020-11-26 Memorial Sloan Kettering Cancer Center Péptidos imunogénicos wt-1 e métodos de uso dos mesmos
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
JP6512569B2 (ja) * 2013-02-05 2019-05-15 日東電工株式会社 経皮投与用ｗｔ１ペプチド癌ワクチンテープ剤
IN2014CH00391A (pt) 2013-02-05 2015-04-03 Nitto Denko Corp
KR102045029B1 (ko) * 2013-02-05 2019-11-14 닛토덴코 가부시키가이샤 점막 투여용 ｗｔ1 펩티드 암 백신 조성물
JP6005305B2 (ja) 2014-02-26 2016-10-12 テラ株式会社 Ｗｔ１抗原性ポリペプチド、及び該ポリペプチドを含む抗腫瘍剤
US10739344B2 (en) * 2014-12-29 2020-08-11 West Virginia University Zinc finger linker (ZnFL) antibody
US10695385B2 (en) * 2015-06-25 2020-06-30 National University Corporation Kobe University Oral cancer vaccine
KR20180094922A (ko) 2015-11-20 2018-08-24 메모리얼 슬로안-케터링 캔서 센터 암 치료 방법 및 조성물
EP3394092A1 (en) * 2015-12-23 2018-10-31 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
CN105713874A (zh) * 2016-01-29 2016-06-29 深圳市中美康士生物科技有限公司 一种抗肿瘤相关抗原wt1特异性ctl及其制备方法
WO2018101309A1 (ja) 2016-11-30 2018-06-07 大日本住友製薬株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
WO2018181648A1 (ja) 2017-03-30 2018-10-04 大日本住友製薬株式会社 Ｗｔ１癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体
KR20210068060A (ko) 2018-09-28 2021-06-08 다이니뽄 스미토모 세이야쿠 가부시키가이샤 주사용 조성물
TW202200188A (zh) 2020-05-12 2022-01-01 日商大日本住友製藥股份有限公司 用以處置癌症之醫藥組合物
WO2023017836A1 (ja) 2021-08-12 2023-02-16 株式会社癌免疫研究所 癌を処置または予防するための医薬組成物および方法
CN113730562B (zh) * 2021-09-10 2024-06-04 中国人民解放军陆军军医大学 以壳聚糖修饰plga的wt1多肽纳米粒疫苗及其制备方法和应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
DE69033127T2 (de) 1989-11-13 1999-10-14 Massachusetts Inst Technology Lokalisation und charakterisierung des wilms-tumor-gens
ATE152915T1 (de) 1991-11-29 1997-05-15 Viagene Inc Immuntherapeutische vektorkonstrukte gegen krebs
WO1994001133A1 (en) 1992-07-08 1994-01-20 Schering Corporation Use of gm-csf as a vaccine adjuvant
JP2735986B2 (ja) 1992-10-16 1998-04-02 株式会社セラリカ野田 癌抑制遺伝子ｗｔの産物に対する抗体
WO1994021287A1 (en) 1993-03-15 1994-09-29 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Peptide coated dendritic cells as immunogens
US5705159A (en) 1993-08-31 1998-01-06 John Wayne Cancer Institute Immunoreactive peptide sequence from a 43 KD human cancer antigen
US5622835A (en) 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
US5670317A (en) 1995-05-08 1997-09-23 Sloan-Kettering Institute For Cancer Research Diagnostic test for the desmoplastic small round cell tumor
DE69636339T2 (de) 1995-06-01 2007-07-19 Kishimoto, Tadamitsu, Tondabayashi Wachstumsinhibitor gegen leukämische zellen, der antisense-oligonukleotidderivate gegen das wilms-tumorgen enthält
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US6818751B1 (en) 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
JP4789095B2 (ja) 1997-07-16 2011-10-05 治夫 杉山 ウイルムス腫瘍遺伝子（ｗｔ１）に対する発現阻害物質を含んで成る固形腫瘍治療剤
JPH1189596A (ja) 1997-09-19 1999-04-06 Takara Shuzo Co Ltd Ｒｎａ量の測定方法並びに測定キット
JPH1189599A (ja) 1997-09-24 1999-04-06 Haruo Sugiyama 補正競合ｒｔ−ｐｃｒ法によるヒトｗｔ１発現定量法
CA2324974A1 (en) 1998-04-01 1999-10-14 The Governors Of The University Of Alberta Compositions and methods for protein secretion
WO1999058135A1 (en) 1998-05-11 1999-11-18 The Salk Institute For Biological Studies Compositions for the treatment of tumors, and uses thereof
CN102198266A (zh) 1998-07-31 2011-09-28 株式会社国际癌症免疫研究所 基于癌抑制基因wt1的产物的癌抗原
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
MXPA01003344A (es) 1998-09-30 2004-04-21 Corixa Corp Composiciones y metodos para inmunoterapia especifica de wt1.
US20030039635A1 (en) * 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
WO2001025273A2 (en) 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US20020061512A1 (en) 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
EP1261711A2 (en) 2000-02-22 2002-12-04 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
CN1314359A (zh) 2000-03-17 2001-09-26 上海博德基因开发有限公司 一种新的多肽——肿瘤抑制因子63和编码这种多肽的多核苷酸
AU2001264559A1 (en) 2000-06-05 2001-12-17 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
AU2001266787A1 (en) 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US7316924B2 (en) 2000-09-18 2008-01-08 Genencor International, Inc. Twin-arginine translocation in Bacillus
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins

Also Published As

Publication number Publication date
ZA200509609B (en) 2007-04-25
US7915393B2 (en) 2011-03-29
WO2004100870A3 (en) 2005-03-31
TW200509967A (en) 2005-03-16
US7553494B2 (en) 2009-06-30
MXPA05011755A (es) 2006-02-17
EP1617863A2 (en) 2006-01-25
MA27873A1 (fr) 2006-05-02
CO5700788A2 (es) 2006-11-30
NO20055347D0 (no) 2005-11-11
KR20060054176A (ko) 2006-05-22
CN1816349A (zh) 2006-08-09
JP2007515393A (ja) 2007-06-14
US20040018204A1 (en) 2004-01-29
RU2005137167A (ru) 2006-06-27
NO20055347L (no) 2006-01-27
WO2004100870A2 (en) 2004-11-25
EP1617863A4 (en) 2007-12-19
CA2523943A1 (en) 2004-11-25
US20090312403A1 (en) 2009-12-17
AU2004238226A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
BRPI0409879A (pt) composições e métodos para imunoterapia especìfica wt1
BR9914116A (pt) Composições e métodos para imunoterapia especìfica de wt1
DE60232102D1 (de) Zusammensetzungen und Verfahren zur WT1-spezifischen Immuntherapie
ATE402189T1 (de) Verbindungen und methoden zur wt1-spezifischen immuntherapie
WO2001025273A3 (en) Compositions and methods for wt1 specific immunotherapy
EA201201533A1 (ru) Prlr-специфическое антитело и его применения
GB0411186D0 (en) Biological products
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
NZ593289A (en) Anti-neuropilin-1 antibodies for treating angiogenesis
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
DE122009000069I1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
BRPI0515721A (pt) uso de um inibidor de src cinase e um inibidor de bcr-abl, composição farmacêutica e combinação
CA2093667A1 (en) Mouse monoclonal antibodies and uses thereof
DE60235005D1 (de) Nachweis der instabilität von mikrosatelliten und
ATE407698T1 (de) Zusammensetzungen und verfahren zur behandlung von entzündlicher darmerkrankung
BR0314369A (pt) Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado
MX2009001341A (es) Anticuerpos especificos de ephb3 y usos de los mismos.
BR0314716A (pt) Anticorpos de subunidade alfa de lfa-1 e métodos de uso
BR0111024A (pt) Composições e métodos para a terapia e diagnóstico de câncer de mama
BR112021016923A2 (pt) Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits
DE69839943D1 (de) Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen
BR0211762A (pt) Certos policetìdeos substituìdos, composições farmacêuticas contendo os mesmos e seu uso no tratamento de tumores
MX2023007302A (es) Anticuerpos contra la integrina alfa 11 beta 1.
BR0310027A (pt) Métodos de empregar uma combinação de uma 3-heteroaril-2-indolinona e um inibidor de ciclooxigenase-2 para o tratamento de neoplasia

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.